First European Conference on SRS/SBRT and IG-IMRT Held in Milan

AsiaNet 52293

SUNNYVALE, California, 4 Mar. 2013 /PRN=KYODO JBN/ --

     Accuray Incorporated [http://www.accuray.com/ ] (Nasdaq: ARAY

[http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=ARAY ]), today

announced highlights from the First European Conference on stereotactic

radiosurgery/stereotactic body radiation therapy (SRS/SBRT) and image-guided

intensity-modulated radiation therapy (IG-IMRT), hosted in partnership with the

Istituto Europeo di Oncologia Milano and the Universita degli studi di Milano,

held in Milan, Italy on February 22-23, 2013.

    The conference "Radiation Oncology: can we still treat without image

guidance?" was attended by more than 400 healthcare professionals, including

radiation oncologists, medical physicists and hospital administrators from 32

countries. Outcomes of recent research in areas such as central nervous system

(CNS), head and neck, breast, lung, gastrointestinal (GI), pelvis, total marrow

irradiation (TMI) and pediatrics were presented.

    The independent Scientific Committee, led by Prof. Roberto Orecchia

(Istituto Europeo di Oncologia Milano, Italy) and Prof. Eric Lartigau (Centre

Oscar Lambret, Lille, France), focused on new developments in the field and

developed an educational event to discuss the need of image guidance for a

variety of clinical indications in modern radiation therapy. "Daily image

guidance is crucial for all high-precision treatments, also for palliative

treatments" said Prof. Eric Lartigau.

    "The TomoTherapy(R) System provides an automatic process that makes our

daily work easy" said Prof. Dirk Verellen, UZ Brussel.

    Prof. Ben Heijmen, Erasmus MC-Daniel den Hoed Cancer Center of Rotterdam,

said "Additionally, dose to the healthy tissue can be strongly reduced using

optimal and numerous non-coplanar beams when treating prostate cancer"

comparing non-coplanar treatments to coplanar treatments.

    "There are non-adaptive and real-time adaptive solutions, but the only

solution that adapts for target motion in real-time, available clinically, is

the CyberKnife(R) System", added Dr. Iciar Santa Olalla.

    About Accuray

    Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that

develops, manufactures and sells personalized, innovative treatment solutions

that set the standard of care with the aim of helping patients live longer,

better lives. The Company's leading-edge technologies deliver the full range of

radiation therapy and radiosurgery treatments.

    Safe Harbor Statement Statements made in this press release that are not

statements of historical fact are forward-looking statements and are subject to

the "safe harbor" provisions of the Private Securities Litigation Reform Act of

1995. Forward-looking statements in this press release relate, but are not

limited, to clinical applications, clinical results, patient outcomes, and the

Company's leadership position in radiation oncology innovation. Forward-looking

statements are subject to risks and uncertainties that could cause actual

results to differ materially from expectations, including risks detailed from

time to time under the heading "Risk Factors" in the company's report on Form

10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on

November 8, 2012 & February 6, 2013, and as updated periodically by our other

filings. Forward-looking statements speak only as of the date the statements

are made and are based on information available to the Company at the time

those statements are made and/or management's good faith belief as of that time

with respect to future events. The Company assumes no obligation to update

forward-looking statements to reflect actual performance or results, changes in

assumptions or changes in other factors affecting forward-looking information,

except to the extent required by applicable securities laws. Accordingly,

investors should not place undue reliance on any forward-looking statements.

    Contacts

    Anja Kleber

    Marketing Director

    Tel +33(0)1-55-23-20-20

    akleber@accuray.com

    Sophie Baumont

    Edelman Paris

    Tel +33(0)1-56-69-75-94

    sophie.baumont@edelman.com

    SOURCE: Accuray Incorporated